Details

Autor(en) / Beteiligte

• Welton, Amanda J
• Vickers, Madge R
• Kim, Joseph
• Ford, Deborah
• Lawton, Beverley A
• MacLennan, Alastair H
• Meredith, Sarah K
• Martin, Jeannett
• Meade, Tom W

Titel

Health related quality of life after combined hormone replacement therapy: randomised controlled trial

Ist Teil von

• BMJ (British Medical Journal), 2008-09, Vol.337 (7669), p.a1190-553

Auflage

International edition

Ort / Verlag

England: BMJ Publishing Group

Erscheinungsjahr

2008

Link zum Volltext

Quelle

Applied Social Sciences Index & Abstracts (ASSIA)

Beschreibungen/Notizen

• To assess the effect of combined hormone replacement therapy (HRT) on health related quality of life. Randomised placebo controlled double blind trial. General practices in United Kingdom (384), Australia (94), and New Zealand (24). Postmenopausal women aged 50-69 at randomisation; 3721 women with a uterus were randomised to combined oestrogen and progestogen (n=1862) or placebo (n=1859). Data on health related quality of life at one year were available from 1043 and 1087 women, respectively. Conjugated equine oestrogen 0.625 mg plus medroxyprogesterone acetate 2.5/5.0 mg or matched placebo orally daily for one year. Health related quality of life and psychological wellbeing as measured by the women's health questionnaire. Changes in emotional and physical menopausal symptoms as measured by a symptoms questionnaire and depression by the Centre for Epidemiological Studies depression scale (CES-D). Overall health related quality of life and overall quality of life as measured by the European quality of life instrument (EuroQol) and visual analogue scale, respectively. After one year small but significant improvements were observed in three of nine components of the women's health questionnaire for those taking combined HRT compared with those taking placebo: vasomotor symptoms (P<0.001), sexual functioning (P<0.001), and sleep problems (P<0.001). Significantly fewer women in the combined HRT group reported hot flushes (P<0.001), night sweats (P<0.001), aching joints and muscles (P=0.001), insomnia (P<0.001), and vaginal dryness (P<0.001) than in the placebo group, but greater proportions reported breast tenderness (P<0.001) or vaginal discharge (P<0.001). Hot flushes were experienced in the combined HRT and placebo groups by 30% and 29% at trial entry and 9% and 25% at one year, respectively. No significant differences in other menopausal symptoms, depression, or overall quality of life were observed at one year. Combined HRT started many years after the menopause can improve health related quality of life. ISRCTN 63718836.